Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Monoclonal Antibodies
"Local But No Systemic Immunomodulation by Intraperitoneal Treatment of Advanced Ovarian Cancer with Autologous T Lymphocytes Re-Targeted by a Bi-Specific Monoclonal Antibody."
November 24th, 1997
According to the authors' abstract of an article published in International Journal of Cancer, "We have reported a 27% overall anti-tumor response using i.p. immunotherapy of advanced ovarian carcinoma with autologous, ex vivo expanded, T lymphocytes re-targeted with bi-specific monoclonal antibody OC/TR, combined with soluble OC/TR and low-dose recombinant interleukin-2 (IL-2). This treatment had no effect on extraperitoneal disease. Therefore we studied in 13 patients whether this immunotherapeutic protocol resulted only in local or also in systemic immunomodulation. The phenotype of the ex vivo expanded lymphocytes was mainly CD3+, 4-, 8+,...
Source: Cancer Weekly (1997-11-24)
|
|
Advertisement |
|
|
